| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 02/28/2001 | CN1285817A Novel tricyclic compounds, preparation method and pharmaceutical compositions containing same |
| 02/28/2001 | CN1285748A Use of 9-deoxy-2', 9-alpha-methano-3-oxa-4,5,6-trinor-3, 7-(1,'3'-interphenylene)-13, 14-dihydro-prostaglandin F, to treat peripheral vascular disease |
| 02/28/2001 | CN1285739A High drug load immediate and modified release oral dosage formulations and process for their production |
| 02/28/2001 | CN1285738A Novel oral dosage form for carvedilol |
| 02/28/2001 | CN1285358A Gene relative peptide derivant having calcitonin and preparation process thereof |
| 02/28/2001 | CN1285208A Sanhuang hypotensor capsule |
| 02/28/2001 | CN1285202A Huoqingzhengyang medicine |
| 02/28/2001 | CN1285198A Solid beverage for prevention and control of essential hypertension and productive method thereof |
| 02/28/2001 | CN1285188A Thermal formed solid releasing-controlled medicinal composition |
| 02/28/2001 | CN1285153A Apocynum venetum health care tea |
| 02/28/2001 | CN1062555C Substituted benzyloxy carbonyl guanidine, its prepn. method, and application of the same as medicament and medicament containing the same |
| 02/28/2001 | CN1062554C Substituted guanidine cinnamate, its prepn., its application as medicine or diagnosing agent and medicine containing the compound |
| 02/28/2001 | CN1062454C Inhalant for preventing and remitting acute attack of cardio-cerebral disease and preparation thereof |
| 02/28/2001 | CN1062453C Medicine for preventing and controlling brain angiopathy |
| 02/28/2001 | CA2317097A1 Process for making 5-lipoxygenase inhibitors having varied heterocyclic ring systems |
| 02/28/2001 | CA2316748A1 Process for making 5-lipoxygenase inhibitors having varied heterocyclic ring systems |
| 02/27/2001 | USRE37077 Adenosine derivatives and pharmaceutical composition thereof |
| 02/27/2001 | US6194585 Process for preparing 5-lipoxygenase inhibitors |
| 02/27/2001 | US6194578 Growth hormone secretagogues; useful for prophylaxis and therapy of osteoporosis and/or frailty, insulin resistance in mammals, congestive heart failure, obesity, accelerating bone fracture repair reducing cachexia and protein loss |
| 02/27/2001 | US6194458 1-(2-methoxyphenyl)-1-oxo-2-aza-(s)-4-i-butyl-4-phenylbutane, for example; treating various conditions including transplantation rejection of organs or tissues in a patient; immunosuppressant compositions |
| 02/27/2001 | US6194454 Cyano containing oxamic acids and derivatives as thyroid receptor ligands |
| 02/27/2001 | US6194449 Allosteric adenosine receptor modulators |
| 02/27/2001 | US6194448 N, N-disubstituted amides that inhibit the binding of integrins to their receptors |
| 02/27/2001 | US6194424 Arylacetamides and their use as medicaments |
| 02/27/2001 | US6194410 Antiserotonine agents; nervous system and psychological disorders |
| 02/27/2001 | US6194405 3,3a,8,12b-tetrahydro-n-methyl-2h-dibenzo(3,4:6,7)-cyclohepta( 1,2-b)-furan-2-methanamine, for example; anxiolytic agents, antidepressants, sleep and sexual disorders, psychological, cardiovascular and gastrointestinal disorders |
| 02/27/2001 | US6194392 Administering to a patient suffering from swelling associated with brain tumours involving tissue of the group consisting of underperfused tissue and pathological tissue an antiswelling agent and a hyaluronic acid to aid penetration |
| 02/27/2001 | US6194020 Conserving procyanidins(catechins); candy |
| 02/27/2001 | US6194004 Dry mix formulation for bisphosphonic acids |
| 02/27/2001 | US6193965 Administering therapeutically effective amount of reagent which modulates kinase activity for treating cell proliferative disorder associated with c-jun n-terminal kinase disorder, |
| 02/27/2001 | US6193957 For prophylaxis and therapy of airway hyperresponsiveness or inflammatory reactions, e.g., asthma, allergic rhinitis, allergic dermatitis, allergic conjunctivitis, inflammatory bowel disease or rheumatoid arthritis |
| 02/27/2001 | CA2316662A1 Use of crf antagonists and related compositions |
| 02/27/2001 | CA2194370C Attenuation of wound healing processes |
| 02/27/2001 | CA2124206C Indole derivatives |
| 02/27/2001 | CA2081205C Steroids which inhibit angiogenesis |
| 02/27/2001 | CA2012267C Interphenylene 7-oxabicycloheptyl substituted heterocyclic amide prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease |
| 02/22/2001 | WO2001013108A1 Method for identifying modulating compounds of neurotransmitters |
| 02/22/2001 | WO2001013031A2 Dose of an angiogenic factor and method of administering to improve myocardial blood flow |
| 02/22/2001 | WO2001012819A2 Protein phosphatases and diagnosis and treatment of phosphatase-related disorders |
| 02/22/2001 | WO2001012818A1 Neutral cerebral-sphingomyelinase |
| 02/22/2001 | WO2001012815A1 Coxsackie virus-derived vector system for gene transfer |
| 02/22/2001 | WO2001012812A2 Baff receptor (bcma), an immunoregulatory agent |
| 02/22/2001 | WO2001012809A2 Heterodimeric vegf variants used for inhibiting angiogenesis |
| 02/22/2001 | WO2001012805A1 Methods for diagnosis and treatment of human diseases including hypertension |
| 02/22/2001 | WO2001012790A2 Isomerase proteins |
| 02/22/2001 | WO2001012786A1 Retinoid receptor interacting polynucleotides, polypeptides, and antibodies |
| 02/22/2001 | WO2001012775A2 25 human secreted proteins |
| 02/22/2001 | WO2001012673A1 Pgpcr-3 polypeptides and dna sequences thereof |
| 02/22/2001 | WO2001012671A1 Human tumor necrosis factor receptor tr16 |
| 02/22/2001 | WO2001012669A1 Vegf-d and angiogenic use thereof |
| 02/22/2001 | WO2001012664A2 Notch receptor ligands and uses thereof |
| 02/22/2001 | WO2001012633A1 Water soluble sdz-rad esters |
| 02/22/2001 | WO2001012628A1 Pharmaceutical compositions containing thiazolidinedione derivatives and process for their preparation |
| 02/22/2001 | WO2001012627A1 Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| 02/22/2001 | WO2001012621A1 INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES |
| 02/22/2001 | WO2001012618A1 Dihydroaminobenzo[b]- and [c]furans as retinoid-like agents |
| 02/22/2001 | WO2001012611A1 Pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 02/22/2001 | WO2001012608A1 Quinoline compounds and process for producing the same |
| 02/22/2001 | WO2001012603A1 Indole derivatives, process for their preparation, pharmaceutical compositions containing them and their medicinal application |
| 02/22/2001 | WO2001012602A1 Condensed indoline derivatives and their use as 5ht, in particular 5ht2c, receptor ligands |
| 02/22/2001 | WO2001012601A1 Novel anilide derivatives or salts thereof and drugs containing the same |
| 02/22/2001 | WO2001012598A2 METHODS OF INHIBITING BINDING OF β-SHEET FIBRIL TO RAGE AND CONSEQUENCES THEREOF |
| 02/22/2001 | WO2001012596A1 Prostaglandin derivatives |
| 02/22/2001 | WO2001012592A2 Hydroxamic acid compounds useful as matrix metalloproteinase inhibitors |
| 02/22/2001 | WO2001012584A2 Pharmaceutical compounds |
| 02/22/2001 | WO2001012233A2 Sustained release formulation of a peptide |
| 02/22/2001 | WO2001012226A1 Angiogenesis inhibitors comprising as the active ingredient compound having chymase inhibitory effect |
| 02/22/2001 | WO2001012212A1 Inhibitors of the lectin complement pathway (lcp) and their use |
| 02/22/2001 | WO2001012210A1 Methods and compositions useful for modulation of angiogenesis using tyrosine kinase raf and ras |
| 02/22/2001 | WO2001012206A2 Soy-glycine extracts and aromatase inhibitors for positively influencing collagen |
| 02/22/2001 | WO2001012198A1 Remedies for myocardial infarction |
| 02/22/2001 | WO2001012195A2 Use of morphine derivatives as medicaments for the treatment of neuropathic problems |
| 02/22/2001 | WO2001012193A1 Pharmaceutical agent comprising a benzamide derivative as active ingredient |
| 02/22/2001 | WO2001012189A1 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents |
| 02/22/2001 | WO2001012188A1 3(5)-ureido-pyrazole derivatives, process for their preparation and their use as antitumor agents |
| 02/22/2001 | WO2001012180A2 Peroxovanadium compounds as protein tyrosine phosphatase (ptp) inhibitors: their inhibitory effects on angiogenesis, restenosis and the production of endothelins, and their stimulating effects on the immune responce |
| 02/22/2001 | WO2001012155A1 Compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
| 02/22/2001 | WO2000077246A3 A METHOD FOR IDENTIFYING A DRUG CANDIDATE HAVING AN INHIBITORY ACTION ON FVII-TF ACTIVITY, AND FVIIa/TF ACTIVITY INHIBITING COMPOUNDS |
| 02/22/2001 | WO2000077179A3 Human poly(adp-ribose) polymerase 2 materials and methods |
| 02/22/2001 | WO2000071538A3 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives |
| 02/22/2001 | WO2000055126A3 N-cyanomethylamides as protease inhibitors |
| 02/22/2001 | WO2000023100A8 Genes and proteins predictive and therapeutic for renal disease and associated disorders |
| 02/22/2001 | WO1999063996A8 Multivalent agonists, partial agonists, inverse agonists and antagonists of the 5ht2 receptors |
| 02/22/2001 | WO1999063992A8 Novel calcium channel drugs and uses |
| 02/22/2001 | DE19939463A1 Tryptase inhibitors useful e.g. for treating inflammatory or allergic disease, arteriosclerosis or neoplasia, comprising new or known 2-phenethyl-benzimidazole-5-carboxamides |
| 02/22/2001 | DE19939095A1 Von Coxsackieviren abgeleitetes Vektorsystem für Gentransfer Of coxsackie-derived vector system for gene transfer |
| 02/22/2001 | CA2698353A1 Pharmaceutical compounds |
| 02/22/2001 | CA2391319A1 Water soluble sdz-rad esters |
| 02/22/2001 | CA2383691A1 Human tumor necrosis factor receptor tr16 |
| 02/22/2001 | CA2383268A1 Pyrazoloanthrone and derivatives thereof as jnk inhibitors and their compositions |
| 02/22/2001 | CA2383154A1 Baff receptor (bcma), an immunoregulatory agent |
| 02/22/2001 | CA2382749A1 Amines substituted with a dihydro-isobenzofuranyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity |
| 02/22/2001 | CA2382265A1 Prostaglandin derivatives |
| 02/22/2001 | CA2382251A1 Methods for diagnosis and treatment of human diseases including hypertension |
| 02/22/2001 | CA2382148A1 25 human secreted proteins |
| 02/22/2001 | CA2382095A1 Methods of inhibiting binding of .beta.-sheet fibril to rage and consequences thereof |
| 02/22/2001 | CA2382090A1 Coxsackie virus-derived vector system for gene transfer |
| 02/22/2001 | CA2382019A1 Isomerase proteins |
| 02/22/2001 | CA2382018A1 Retinoid receptor interacting polynucleotides, polypeptides, and antibodies |
| 02/22/2001 | CA2381985A1 Vegf-d and angiogenic use thereof |